Yatharth Hospital & Trauma Care Services Limited (NSE:YATHARTH)
India
· Delayed Price · Currency is INR | Market Cap | 75.21B |
| Revenue (ttm) | 10.95B |
| Net Income (ttm) | 1.67B |
| Shares Out | 96.35M |
| EPS (ttm) | 17.36 |
| PE Ratio | 44.97 |
| Forward PE | 33.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 216,314 |
| Average Volume | 430,335 |
| Open | 782.95 |
| Previous Close | 780.60 |
| Day's Range | 774.10 - 793.70 |
| 52-Week Range | 451.50 - 843.70 |
| Beta | 0.79 |
| RSI | 62.99 |
| Earnings Date | May 22, 2026 |
About NSE:YATHARTH
Yatharth Hospital & Trauma Care Services Limited, together with its subsidiaries, owns and operates super-specialty hospitals in India. The company offers services in the areas of medicine, cardiology, neurosciences, general surgery, nephrology and urology, pediatrics, gastroenterology, pulmonology, gynecology, orthopedics, spine and rheumatology, plastic and cosmetic surgery, ear, nose, throat, endocrinology, critical care, dermatology, nuclear medicine, and cancer and bone marrow transplant. It also provides services in the areas of GI surger... [Read more]
Financial Performance
In fiscal year 2025, NSE:YATHARTH's revenue was 8.86 billion, an increase of 31.55% compared to the previous year's 6.73 billion. Earnings were 1.31 billion, an increase of 14.04%.
Financial StatementsNews
Yatharth Hospital & Trauma Care Services Transcript: Q3 25/26
Q3 FY26 saw record revenue and profitability, driven by strong growth in both existing and new hospitals, with ARPOB and EBITDA margins improving year-over-year. Expansion plans target 5,000 beds in 3-4 years, with a focus on higher-value specialties and reducing government payer mix.
Yatharth Hospital & Trauma Care Services Transcript: Q2 25/26
Record revenue and EBITDA growth driven by new hospital additions and mature hospital strength, with robust ARPOB and occupancy metrics. Expansion continues in North India, supported by strong cash, no debt, and a positive outlook for margins and revenue growth.
Yatharth Hospital & Trauma Care Services Transcript: Q1 25/26
Q1 FY 2026 saw record revenue and profit, with 22% YoY revenue growth and 23% net profit growth, driven by new hospital ramp-ups and super specialty focus. New Delhi and Faridabad hospitals are set to boost growth, with EBITDA margins expected to remain around 24%-25% for FY 2026.
Yatharth Hospital & Trauma Care Services Transcript: Q4 24/25
FY 2025 saw a 4.6% revenue decline due to payment delays and project award lags, but EBITDA margin improved to 12.8% and PAT rose 8%. The order book hit a record INR 36,869 crore, with strong growth and margin guidance for FY 2026.
Yatharth Hospital & Trauma Care Services Transcript: Q3 24/25
Revenue grew 31% YoY in Q3 FY2025, with strong ARPOB and super-specialty expansion driving results. New hospital acquisitions and investments in advanced therapies are expected to sustain growth, while income tax matters are being resolved without material impact.
Yatharth Hospital & Trauma Care Services Transcript: Q2 24/25
Revenue grew 34% year-over-year to INR 1,713 million, with profit after tax up 70% and EBITDA margin at 26.6%. IPO proceeds enabled debt repayment and expansion plans, while super-specialty and international business are set to drive future growth.